It’s the hot-shot fix that took Hollywood — and now high school — by storm. Ozempic and other so-called “miracle” weight-loss ...

Cigna Healthcare, the health benefits division of the Cigna Group, has released a set of digital tools aimed at improving the ...

Some Blue Cross and Blue Shield insurers dipped their toes into expanding coverage for blockbuster weight-loss drugs, then ...

A pharmacy benefit that caps monthly co-pays for the weight loss drugs semaglutide (Wegovy) and tirzepatide (Zepbound) at $200 was introduced by Evernorth, Cigna’s health services division ...

The Novo Nordisk CEO change and the Evernorth copay cap move may be a sign that competition is starting to bring Wegovy and Zepbound prices back to earth. The future impact: One question is when ...

The disruption came from Cigna’s Evernorth division, which introduced a $200 monthly cap for Wegovy and Zepbound, two blockbuster weight-loss drugs. This move drastically improves affordability and ...

Shares of telehealth company Hims & Hers Health (NYSE:HIMS) fell 6.3% in the afternoon session after Cigna Group's Evernorth division introduced a monthly $200 price cap for weight-loss medications ...

The company's Evernorth Health Services subsidiary has launched a pharmacy benefit offering that caps monthly copayments for Wegovy and Zepbound, two blockbuster glucagon-like peptide-1 agonists, or ...

Cigna will cap out-of-pocket costs at $200 per month for patients using the weight-loss drugs Wegovy and Zepbound through an add-on to its pharmacy benefit management plans, the company announced on ...

The reduced pricing is the result of direct negotiations between Evernorth and the drugs’ manufacturers. Wegovy has a list price of $1,349.02/package, while Zepbound comes at a list price of $ ...

Evernorth said that through direct negotiations with Novo Nordisk and Eli Lilly, patients’ monthly copay costs for Wegovy ...